Clinical Report: Phase 3 Ixo-Vec Program Advances

Overview

The phase 3 development program for ixoberogene soroparvovec (ixo-vec) in neovascular age-related macular degeneration (nAMD) is progressing, with the ARTEMIS and AQUARIUS studies evaluating its efficacy and safety. Early trials indicate that a single injection may provide sustained aflibercept expression and significantly reduce treatment burden.

Background

Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss in older adults, necessitating frequent anti-VEGF injections. Current treatment regimens often lead to variability in retinal thickness and poorer long-term outcomes. The development of durable therapies like gene therapy could address these challenges and improve patient care.

Data Highlights

No numerical data available in the source material.

Key Findings

• The ARTEMIS and AQUARIUS studies are assessing the efficacy of ixo-vec in nAMD patients.
• Previous trials (OPTIC and LUNA) demonstrated sustained aflibercept expression for 4-5 years post-injection.
• Patients in OPTIC averaged fewer than 2 injections annually after treatment, down from approximately 10 prior to enrollment.
• Visual acuity and central subfield thickness remained stable across both OPTIC and LUNA studies.
• In LUNA, treatment burden decreased by nearly 90% during the first 2 years of follow-up.
• No significant safety concerns were reported, with mild to moderate inflammation manageable with corticosteroids.

Clinical Implications

The findings suggest that ixo-vec could significantly reduce the frequency of injections required for nAMD patients, addressing a major unmet need in the treatment landscape. Clinicians may consider gene therapy as a viable long-term solution for patients with high treatment burdens.

Conclusion

The ongoing phase 3 studies of ixo-vec hold promise for transforming the management of nAMD by potentially offering a durable treatment option that reduces the need for frequent injections.

Related Resources & Content

1. Ophthalmology Management, 2024 -- Adverum’s Ixo-vec Shows Positive Results in nAMD Trials
2. Retinal Physician, 2024 -- Phase 2 LUNA Trial Data Presented at ASRS
3. Retinal Physician, 2025 -- Adverum Initiates ARTEMIS Study
4. PubMed, 2025 -- Age-Related Macular Degeneration Preferred Practice Pattern®
5. ScienceDirect, 2025 -- Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial
6. Retinal Physician — SUBSPECIALTY NEWS: New product launches in laser and surgery, progress on clinical trials in dry AMD, and more.
7. Age-Related Macular Degeneration Preferred Practice Pattern® - PubMed
8. Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial - ScienceDirect
9. advm-20250930